Diltiazem Articles
Hoechst/Rhone-Poulenc Merger Looks More Likely
17 November 1998
Hoechst Marion Roussel Invests In Canada
16 November 1998
Andrx Submits ANDA For Bioequivalent Drugs
23 September 1998
Hoechst And Andrx Accused Of Price-Fixing
24 August 1998
Hoechst Sales Down 18% But HMR Pipeline Strong
19 August 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
First Generic Cardizem CD
22 July 1998
Abbott Labs Impacted By Strength Of Dollar
14 July 1998
New Labeling For Pravachol
15 June 1998
SkyePharma Benefits From Lilly Trial Advance
15 May 1998
Hoechst Confirms Life Science Focus
5 May 1998
Elan Posts Record Growth In 1st Quarter 1998
27 April 1998
Synthelabo Predicts Strong Opportunities For Growth
6 April 1998
Bad Times Soon Over, Says Hoechst Marion Roussel
12 March 1998
$22 Billion World Drug Delivery Market In 1996
4 March 1998
HMR Launches Teczem In USA
19 February 1998
Strong Growth At Elan Corp, Net Income Up 51%
9 February 1998
FDA Approves Biovail's Tiazac
5 February 1998
Teva Enters Marketing Deal With Biovail
18 December 1997
Swedes May Set Up Indian R&D Facility
10 November 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
Biovail Earnings Boosted By Tiazac
7 August 1997
Antihypertensive Sales "Set To Decline"
1 August 1997
Centeon Impact Still Hitting R-PR Results
29 July 1997
Ethical Holdings Suffers Delay To London Listing
2 July 1997
Takeover Speculation On Andrx
25 June 1997
Posicor Approved In USA For Hypertension, Angina
25 June 1997
Synthelabo Presents 1996 Highlights, New Research
21 April 1997
Elan Corp Takes One-Time Charge At Nine Months
10 February 1997
DSM Sues Sepracor And Tanabe
20 January 1997
Fears Over Tiazac Hit Biovail
23 December 1996
Biovail Shares Soar On Firm's Good News
9 December 1996
Further Profits Warnings From Forest Labs
9 December 1996
Patent Dispute Settled Between Biovail And Elan
2 December 1996
HMR's Teczem In USA
11 November 1996
Hoechst Aims For Two NCEs Each Year
23 September 1996
Biovail Suit To Challenge Dirty Tricks
2 September 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
Patent Expiries Set To Drive Generics Boom
22 July 1996
"Generics Could Save Canadians C$30 Mill"
10 June 1996
US Corporate Results Round-Up
27 May 1996
Strong Year-End For Elan Corporation
13 May 1996
What Future For Synthelabo In The USA?
22 April 1996
Cardizem Lyo-Ject Launched
1 April 1996
Extended-Release Diltiazem Available
19 February 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
FDA Panel Verdict On Calcium Blockers
5 February 1996
Transition For AHP in 1995; Year-End Results
5 February 1996
Rhone-Poulenc Rorer's "Year Of Firsts"
5 February 1996
1995 Sales Up 14.8% At Synthelabo
29 January 1996
Synthelabo Strong In Europe And Expanding
30 October 1995
US 3rd Qrt Results: Strong Gains For Pfizer, Lilly
23 October 1995
R-PR Gets US Approval For Nasacort AQ
16 October 1995
Galephar-Tiazac/ Biovail Deal Clarified
9 October 1995
Biovail acquires Galephar
25 September 1995
Hoechst Marion Roussel Begins To Take Shape
25 September 1995
Calcium Blockers In Heart Failure: PRAISE Study
4 September 1995
JAMA Study Ups Debate Over Calcium Blockers
4 September 1995
Generics: A Passage Through Time
4 September 1995
First-Half Profits Surge At Rhone-Poulenc
31 July 1995
Good Performance Forecast For Euro Drugmakers
26 June 1995
Teva gets approval for flurbiprofen and diltiazem
19 June 1995
Benefits Of Drug Delivery Systems For Generics
5 June 1995
NEW YORK STOCK COMMENT
22 May 1995
Synthelabo Aims For 10 bn Francs In Sales In 1996
17 April 1995
Biovail Resolves Legal Problems
17 April 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
Watson Offers $606.5 Million For Circa
10 April 1995
Calcium Channel Blockers Raise Heart Attack Risk?
20 March 1995
Hoechst Offers $7 Billion For Marion Merrell Dow
6 March 1995
Diltiazem Dispute
27 February 1995
Diltiazem Review News
6 February 1995
1994 Transitional For R-PR With Better Second Half
6 February 1995
Sales at Synthelabo Grow 12.7% in 1994
6 February 1995
...And Israel's Teva Recommended
2 January 1995
Wille Labs Secures Generics deal
12 December 1994
Tanabe Reports Revenue Decline
5 December 1994
Biovail Seeks Damages From Marion Merrell Dow
5 December 1994
Lower Earnings For Some US Drugmakers In 3rd Qtr
7 November 1994
Biovail Files Suit Against MMD
31 October 1994
Rhone-Poulenc Rorer's 3rd Qtr As Expected
31 October 1994
USA's Top-Selling Drugs In 1993
24 October 1994
Second Launch Of Jago Geomatrix System
15 August 1994
CORANGE 2000: A REVIEW AND FUTURE STRATEGY
11 July 1994
DOW CHEM MAY SELL ITS MMD STAKE
27 June 1994
DILTIAZEM PROCESS PATENT AFFIRMED
20 June 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
DECLINING 1st QTR FOR RHONE-POULENC RORER
2 May 1994
ISRAEL'S TEVA BUYS STAKE IN PROGRAPHARM
18 April 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
BUY RECOMMENDATION FOR TEVA STOCK
11 April 1994
ACTISITE CLEARED FOR MARKET IN USA
11 April 1994
EFFECTS OF JAPAN NHI PRICE CUTS
7 March 1994
THE FUTURE FOR THE US DRUG MARKET
28 February 1994
N AMERICAN PHARMA MARKET STUDIED
28 February 1994
OPPORTUNITIES FROM DRUG DELIVERY SYSTEMS
21 February 1994
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
